These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 17691977)

  • 1. 5HT1F- and 5HT7-receptor agonists for the treatment of migraines.
    Agosti RM
    CNS Neurol Disord Drug Targets; 2007 Aug; 6(4):235-7. PubMed ID: 17691977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting to 5-HT1F receptor subtype for migraine treatment: lessons from the past, implications for the future.
    Mitsikostas DD; Tfelt-Hansen P
    Cent Nerv Syst Agents Med Chem; 2012 Dec; 12(4):241-9. PubMed ID: 22934751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-Hydroxytryptamine(1F) receptors do not participate in vasoconstriction: lack of vasoconstriction to LY344864, a selective serotonin(1F) receptor agonist in rabbit saphenous vein.
    Cohen ML; Schenck K
    J Pharmacol Exp Ther; 1999 Sep; 290(3):935-9. PubMed ID: 10454462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The safety of triptans in the treatment of patients with migraine.
    Jamieson DG
    Am J Med; 2002 Feb; 112(2):135-40. PubMed ID: 11835952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Migraine: pathophysiology, pharmacology, treatment and future trends.
    Villalón CM; Centurión D; Valdivia LF; de Vries P; Saxena PR
    Curr Vasc Pharmacol; 2003 Mar; 1(1):71-84. PubMed ID: 15320857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Profiles of 5-HT 1B/1D agonists in acute migraine with special reference to second generation agents.
    Deleu D; Hanssens Y
    Acta Neurol Belg; 1999 Jun; 99(2):85-95. PubMed ID: 10427351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in 5-HT1B/1D receptor antagonists and agonists and their potential therapeutic applications.
    Slassi A
    Curr Top Med Chem; 2002 Jun; 2(6):559-74. PubMed ID: 12052194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distribution of 5-HT(1B), 5-HT(1D) and 5-HT(1F) receptor expression in rat trigeminal and dorsal root ganglia neurons: relevance to the selective anti-migraine effect of triptans.
    Classey JD; Bartsch T; Goadsby PJ
    Brain Res; 2010 Nov; 1361():76-85. PubMed ID: 20833155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute treatments: some blind alleys.
    Ramadan NM
    Curr Med Res Opin; 2001; 17 Suppl 1():s71-80. PubMed ID: 12463283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective inhibition of 5-HT7 receptor reduces CGRP release in an experimental model for migraine.
    Wang X; Fang Y; Liang J; Yin Z; Miao J; Luo N
    Headache; 2010 Apr; 50(4):579-87. PubMed ID: 20236348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serotonin receptor ligands: treatments of acute migraine and cluster headache.
    Goadsby PJ
    Handb Exp Pharmacol; 2007; (177):129-43. PubMed ID: 17087122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5-HT1F receptor agonists in acute migraine treatment: a hypothesis.
    Ramadan NM; Skljarevski V; Phebus LA; Johnson KW
    Cephalalgia; 2003 Oct; 23(8):776-85. PubMed ID: 14510923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Present and future of 5-HT receptor agonists as antimigraine drugs.
    Pauwels PJ; John GW
    Clin Neuropharmacol; 1999; 22(3):123-36. PubMed ID: 10367177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel potent 5-HT(1F) receptor agonists: structure-activity studies of a series of substituted N-[3-(1-methyl-4-piperidinyl)-1H-pyrrolo[3,2-b]pyridin-5-yl]amides.
    Filla SA; Mathes BM; Johnson KW; Phebus LA; Cohen ML; Nelson DL; Zgombick JM; Erickson JA; Schenck KW; Wainscott DB; Branchek TA; Schaus JM
    J Med Chem; 2003 Jul; 46(14):3060-71. PubMed ID: 12825944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serotonin receptor targeted therapy for migraine treatment: an overview of drugs in phase I and II clinical development.
    Barbanti P; Aurilia C; Egeo G; Fofi L; Palmirotta R
    Expert Opin Investig Drugs; 2017 Mar; 26(3):269-277. PubMed ID: 28103158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drugs targeting 5-hydroxytryptamine receptors in acute treatments of migraine attacks. A review of new drugs and new administration forms of established drugs.
    Tfelt-Hansen PC; Pihl T; Hougaard A; Mitsikostas DD
    Expert Opin Investig Drugs; 2014 Mar; 23(3):375-85. PubMed ID: 24289494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of action of the 5-HT1B/1D receptor agonists.
    Tepper SJ; Rapoport AM; Sheftell FD
    Arch Neurol; 2002 Jul; 59(7):1084-8. PubMed ID: 12117355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological characterization of almotriptan: an indolic 5-HT receptor agonist for the treatment of migraine.
    Bou J; Domènech T; Puig J; Heredia A; Gras J; Fernández-Forner D; Beleta J; Palacios JM
    Eur J Pharmacol; 2000 Dec; 410(1):33-41. PubMed ID: 11134654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological aspects of experimental headache models in relation to acute antimigraine therapy.
    De Vries P; Villalón CM; Saxena PR
    Eur J Pharmacol; 1999 Jun; 375(1-3):61-74. PubMed ID: 10443565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contractile responses to sumatriptan and ergotamine in the rabbit saphenous vein: effect of selective 5-HT(1F) receptor agonists and PGF(2alpha).
    Cohen ML; Schenck K
    Br J Pharmacol; 2000 Oct; 131(3):562-8. PubMed ID: 11015308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.